Markers of Cellular Proliferation, Apoptosis, Estrogen/Progesterone Receptor Expression and Fibrosis in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids

被引:14
|
作者
Szydlowska, Iwona [1 ]
Grabowska, Marta [2 ]
Nawrocka-Rutkowska, Jolanta [1 ]
Piasecka, Malgorzata [2 ]
Starczewski, Andrzej [1 ]
机构
[1] Pomeranian Med Univ, Dept Gynecol Endocrinol & Gynecol Oncol, PL-71252 Szczecin, Poland
[2] Pomeranian Med Univ, Dept Histol & Dev Biol, Zolnierska 48 St, PL-71210 Szczecin, Poland
关键词
uterine myoma; ulipristal acetate; proliferation; apoptosis; fibrosis; estrogen receptor; progesterone receptor; ULIPRISTAL ACETATE; EXTRACELLULAR-MATRIX; ESTROGEN-RECEPTORS; GNRH AGONIST; IN-VIVO; LEIOMYOMA; MYOMA; ENDOMETRIOSIS; MECHANISMS; REDUCTION;
D O I
10.3390/jcm10040562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There appear to be very few data on the exact mechanisms of a selective progesterone receptor modulator action in myomas. The aim of the study was to assess the effects of ulipristal acetate (UPA) on fibroids, especially on estrogen receptor (ER) and progesterone receptor (PR) immunoexpression, proliferation, apoptosis and tissue fibrosis, and to compare the above parameters in untreated (surgical attention only) and UPA-treated leiomyomas. UPA-treated patients were divided into three groups: (1) good response (>= 25% reduction in volume of fibroid), (2) weak response (insignificant volume reduction) and (3) no response to treatment (no decrease or increase in fibroid volume). The study observed a significant decrease in the percentage of collagen volume fraction and ER and PR immunoexpression in the good response group, in the percentage of proliferating cell nuclear antigen (PCNA)- and Ki67-positive cells in the groups with good and weak reactions vs. control group; significantly higher apoptotic index (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells) in the good reaction group vs. control group. The results of the study indicate that a good response to UPA, manifested by a volume reduction of myoma, may be associated with a decrease in fibrosis, ER/PR and PCNA and Ki67 immunoexpression and an increase in cell apoptosis within the myoma.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [21] The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids
    Singh, Sukhbir S.
    Belland, Liane
    Leyland, Nicholas
    von Riedemann, Sarah
    Murji, Ally
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 218 (06) : 563 - +
  • [22] Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids
    Ali, Mohamed
    Al-Hendy, Ayman
    BIOLOGY OF REPRODUCTION, 2017, 97 (03) : 337 - 352
  • [23] Selective estrogen receptor modulator with estrogen does not affect the proliferation and apoptosis of uterine leiomyoma cells
    Lv, Shu-Lan
    Wang, Rui
    Xue, Xue
    Zhao, Lan-Bo
    Tuo, Xiao-Qian
    Ma, Si-Jia
    Liang, Dong-Xin
    Wang, Yi-Ran
    Feng, Xue
    Li, Qing
    Wang, Qi
    Han, Lu
    Li, Qi-Ling
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (09) : 5390 - 5400
  • [24] Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?
    Ciebiera, Michal
    Vitale, Salvatore G.
    Ferrero, Simone
    Vilos, George A.
    Barra, Fabio
    Caruso, Salvatore
    Lagana, Antonio S.
    Sierant, Antoni
    Cianci, Antonio
    Jakiel, Grzegorz
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (03) : 300 - 309
  • [25] Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist
    Yun, Bo Seong
    Seong, Seok Ju
    Cha, Dong Hyun
    Kim, Ji Yeon
    Kim, Mi-La
    Shim, Jeong Yun
    Park, Ji Eun
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 191 : 62 - 67
  • [26] Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas
    Milewska, Gabriela
    Ponikwicka-Tyszko, Donata
    Bernaczyk, Piotr
    Lupu, Oana
    Szamatowicz, Michal
    Sztachelska, Maria
    Pilaszewicz-Puza, Agata
    Koda, Mariusz
    Bielawski, Tomasz
    Zbucka-Kretowska, Monika
    Pawelczyk, Adam
    Tomaszewski, Jakub
    Li, Xiangdong
    Huhtaniemi, Ilpo
    Wolczynski, Slawomir
    Rahman, Nafis A.
    FERTILITY AND STERILITY, 2024, 122 (02) : 341 - 351
  • [27] Re: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids
    Middelkoop, Mei-An
    Huirne, Judith A. F.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (04) : 424 - 425
  • [28] Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas - An immunohistochemical study
    Kelley, TW
    Borden, EC
    Goldblum, JR
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2004, 12 (04) : 338 - 341
  • [29] Re: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids REPLY
    Singh, Sukhbir S.
    Belland, Liane
    Leyland, Nicholas
    von Riedemann, Sarah
    Murji, Ally
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (04) : 425 - 426
  • [30] The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids: an alternative perspective
    Odejinmi, Funlayo
    Annan, Henry
    Mallick, Rebecca
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (02) : 211 - 211